Price Reductions
Reducing the EV price alone cannot make EV-Pem cost-effective at £30,000 per QALY. Concurrent reductions in both EV and pembrolizumab prices could theoretically make EV-Pem cost-effective at £30,000 per QALY. EV-Pem's high cost is driven b…
1 sources - 3 claims
Reducing the EV price alone cannot make EV-Pem cost-effective at £30,000 per QALY. Concurrent reductions in both EV and pembrolizumab prices could theoretically make EV-Pem cost-effective at £30,000 per QALY. EV-Pem's high cost is driven by use of two high-cost agents.